Zealand Pharma A/S holds the cleaner structural position, with the lead spread across valuation and profitability. UCB still has the edge on stability, which keeps the comparison from looking entirely one-sided. In the market, UCB carries the stronger setup — intact trend against Zealand Pharma A/S's broken trend. That leaves a split case: the structural lead stays with Zealand Pharma A/S, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels.
This is not just a one-metric split: both valuation and profitability materially support the lead. The overall score gap is 25 points in favour of Zealand Pharma A/S.
Both operate in: Biotechnology
This comparison is based on industry proximity, not on functional trajectory similarity. UCB.BR and ZEAL.CO share the same industry classification.
For a similarity-based comparison, see how UCB and Zealand Pharma A/S each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Score differences across key dimensions.
Left means cheaper relative valuation. Higher means stronger structure.
Zealand Pharma A/S looks stronger both structurally and on relative valuation.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
The multiple-based pricing edge comes from a trailing P/E that is 30 turns lower.
Stability still leans toward UCB SA, so the lead is real without reading as one-way.
The lead is built on both valuation and profitability — though stability still provides a counterweight.
Break down the UCB.BR vs ZEAL.CO comparison across all dimensions with the full interactive tool.
Explore how UCB.BR and ZEAL.CO each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.